Zidan J, Kuten A, Cohen Y, Robinson E
Cancer. 1987 Jan 1;59(1):24-6. doi: 10.1002/1097-0142(19870101)59:1<24::aid-cncr2820590109>3.0.co;2-m.
Thirty-one patients with Stage III-IV head and neck squamous cell cancer were treated by three courses of combination chemotherapy using bleomycin, methotrexate, and cisplatin followed by a radical course of radiation and in two cases by surgery. Of 29 evaluable patients, 4 (14%) achieved complete remission (CR) with chemotherapy and 13 (45%) had a partial response (PR). With the addition of radiotherapy and surgery, the CR rate increased to 72%. At 30 months the actuarial survival of all evaluable patients was 61% and of complete responders, 76%. Patients with nasopharyngeal cancer had an actuarial survival of 80% at 30 months, whereas patients with squamous malignancies at other sites in the head and neck region had an actuarial survival of only 37%. Side effects were tolerable. It is concluded that complete responders to combination chemotherapy and radiotherapy have a survival benefit at 30 months. The combined approach is most effective in nasopharyngeal cancer.
31例Ⅲ - Ⅳ期头颈部鳞状细胞癌患者接受了三个疗程的联合化疗,化疗药物为博来霉素、甲氨蝶呤和顺铂,随后进行根治性放疗,2例患者接受了手术。在29例可评估患者中,4例(14%)化疗后达到完全缓解(CR),13例(45%)部分缓解(PR)。加上放疗和手术,CR率升至72%。30个月时,所有可评估患者的精算生存率为61%,完全缓解者为76%。鼻咽癌患者30个月时的精算生存率为80%,而头颈部其他部位鳞状恶性肿瘤患者的精算生存率仅为37%。副作用可耐受。结论是联合化疗和放疗的完全缓解者在30个月时有生存获益。联合治疗方法在鼻咽癌中最有效。